Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Myeloid 2

Conditions

Leukemia, Myeloid, Acute 27Myelodysplastic Syndromes 8Myeloproliferative Disorders 4Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Monocytic, Acute 3Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelomonocytic, Acute 2Leukemia 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Lymphoid 1Leukemia, Erythroblastic, Acute 1Disease 1Congenital Abnormalities 1Burkitt Lymphoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 192Methotrexate 106Cytarabine 86fludarabine phosphate 80Busulfan 71Tacrolimus 70Peripheral Blood Stem Cell Transplantation 69Mycophenolic Acid 69Whole-Body Irradiation 68Vincristine 67fludarabine 61Filgrastim 61Etoposide 59Dexamethasone 54Melphalan 52Radiotherapy 47Rituximab 46Cyclosporine 46Doxorubicin 38Antilymphocyte Serum 37Thiotepa 35Granulocyte Colony-Stimulating Factor 35Prednisone 34Mercaptopurine 34blinatumomab 33pegaspargase 27Methylprednisolone 27Daunorubicin 26Clofarabine 26Asparaginase 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × CPX-351 × Clear all
NCT03575325 2024-12-12

Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
11 enrolled 12 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphoid, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02269579 2018-03-14

Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment

Jazz Pharmaceuticals

Phase 2 Withdrawn
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02238925 2017-11-30

An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients

Jazz Pharmaceuticals

Phase 2 Completed
26 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡